Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC

Recently, promising results of the antitumor effects were observed in patients with metastatic castration-resistant prostate cancer treated with (177)Lu-labeled PSMA-ligands. Radionuclide therapy efficacy may even be improved by using the alpha emitter Ac-225. Higher efficacy is claimed due to high...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharmaceutics
Auteurs principaux: Hooijman, Eline L., Chalashkan, Yozlem, Ling, Sui Wai, Kahyargil, Figen F., Segbers, Marcel, Bruchertseifer, Frank, Morgenstern, Alfred, Seimbille, Yann, Koolen, Stijn L. W., Brabander, Tessa, de Blois, Erik
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8153125/
https://ncbi.nlm.nih.gov/pubmed/34068206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics13050715
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires